Story at a glance
- The research found a single dose of either vaccine is more than 80 percent effective at preventing hospitalization in those over 80 around three to four weeks after the dose is administered.
- There’s also some evidence to suggest that the Pfizer vaccine leads to an 83 percent reduction in COVID-19 deaths among that population.
- The report also found people over the age of 70 were shown to have up to 61 percent protection against symptomatic disease with the first dose of the Pfizer-BioNTech vaccine and up to 73 percent from the Oxford-AstraZeneca jab.
Just one dose of either the Pfizer-BioNTech or Oxford-AstraZeneca coronavirus vaccine can reduce the risk of hospitalization from COVID-19 by more than 80 percent in people over the age of 80, according to data from Public Health England (PHE).
The study released by PHE Monday, which has yet to be peer-reviewed, included data from more than 7.5 million people aged 70 and over in England.
Our country is in a historic fight against the Coronavirus. Add Changing America to your Facebook or Twitter feed to stay on top of the news.
The research found a single dose of either vaccine is more than 80 percent effective at preventing hospitalization in those over 80 around three to four weeks after the dose is administered. There’s also some evidence to suggest that the Pfizer vaccine leads to an 83 percent reduction in COVID-19 deaths among that population.
The report also found people over the age of 70 were shown to have up to 61 percent protection against symptomatic disease with the first dose of the Pfizer-BioNTech vaccine and up to 73 percent from the Oxford-AstraZeneca jab.
“This adds to growing evidence showing that the vaccines are working to reduce infections and save lives. While there remains much more data to follow, this is encouraging and we are increasingly confident that vaccines are making a real difference,” Mary Ramsay, PHE head of immunization, said in a statement.
The data comes as some European nations have authorized the AstraZeneca vaccine only for younger adults due to the lack of trial data on its efficacy in older recipients and as the U.K. decided to delay second doses to inoculate more people at a faster rate with the first dose. More than 20 million people have received COVID-19 shots in Britain, more than one-third of all adults in the country.
The AstraZeneca vaccine has yet to receive approval in the U.S.
WHAT YOU NEED TO KNOW ABOUT CORONAVIRUS RIGHT NOW
CALIFORNIA CORONAVIRUS VARIANT IS MORE CONTAGIOUS, NEW RESEARCH SHOWS
A NEW COVID-19 VARIANT IS EMERGING IN NEW YORK CITY, RESEARCHERS SAY
SURPRISING NEW COVID-19 STUDY FINDS VIRUS SURVIVES ON CLOTHING FABRIC FOR DAYS
NEW STUDY SUGGESTS FEW COVID-19 DEATHS OUTSIDE OF WUHAN IN EARLY 2020
HOW COVID-19 VARIANTS STACK UP AGAINST THE VACCINES
Copyright 2023 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
